Digital download
Access the files immediately after checkout.
89bio Porter's Five Forces Analysis
Included with this resource
Word + Excel files
Edit, adapt and present the analysis in familiar formats.
Five competitive forces
Assess rivalry, entry, substitutes, buyers and suppliers.
Market pressure map
See where industry profitability faces the most pressure.
Priority responses
Translate competitive pressure into strategic questions.
Don't Miss the Bigger Picture
89bio faces intense R&D and regulatory pressures typical of biopharma, with supplier concentration for reagents and strong buyer scrutiny from payers and partners. Competitive rivalry is shaped by niche pipeline differentiation, while capital intensity and clinical risk moderate threats of new entrants and substitutes. This brief snapshot only scratches the surface. Unlock the full Porter's Five Forces Analysis to explore 89bio’s competitive dynamics, market pressures, and strategic advantages in detail.
Suppliers Bargaining Power
Concentrated biologics CDMOs
Manufacturing pegozafermin requires specialized biologics CDMOs with FGF21 and PEGylation capabilities. The pool of high-quality suppliers is limited—2024 leaders include Lonza, Catalent, Samsung Biologics and WuXi Biologics—giving them leverage on price, slots and tech-transfer terms. Dual-sourcing is difficult due to process complexity, so any capacity crunch or quality issue can delay trials and commercialization.
Critical raw materials and reagents
Critical inputs for 89bio such as PEGylation polymers, chromatography resins, single-use systems and regulatory-grade cell banks are supplied by a handful of dominant vendors (Sartorius, Cytiva, Thermo Fisher), creating supplier leverage. Lead times frequently run 12–24 weeks and master cell bank development often takes 6–12 months, enhancing negotiation power. Securing long-term supply agreements and safety stocks is essential, and regulatory-grade documentation further locks in specific suppliers.
CROs, clinical sites, and KOL networks
Competition for NASH biopsy-capable sites and experienced CROs is intense as the global CRO market was estimated at $62.5 billion in 2024, driving premium pricing for specialized hepatology expertise. Top hepatology centers and KOLs can dictate timelines, budgets, and protocol nuances, with biopsy screen-failure rates for NASH trials commonly reported around 50%, creating enrollment bottlenecks that raise per-patient costs and sponsor dependence. Preferred partnerships and site networks can partially offset supplier bargaining power by securing faster enrollment and negotiated rates.
Specialized analytics and biomarkers
Specialized analytics and biomarkers (MRI-PDFF, histopathology reads, bioanalytical assays) are niche services with limited global providers; while over 26,000 CLIA-certified labs exist in the US (2024), few meet consistent regulatory standards for multicenter trials, so switching labs risks assay drift and data discontinuity, increasing supplier leverage on price and service terms.
- MRI-PDFF: limited qualified sites
- High switching risk: assay drift, lost continuity
- Supplier power: pricing and contract terms rise
Cold-chain logistics and fill-finish
Pegozafermin requires strict cold-chain stability and sterile fill-finish under rigorous QA; qualified biologics CDMOs are concentrated and booking windows are often many months, giving suppliers leverage. Process deviations can lead to batch loss and regulatory holds, amplifying supplier power, so long-term capacity reservations are strategically important.
- Concentrated qualified CDMOs
- Booking windows: many months
- Deviations risk batch loss and regulatory holds
- Long-term capacity reservations critical
CDMO bottlenecks heighten supply risk — 12–24 weeks lead times, premium CRO pricing
Manufacturing pegozafermin depends on a small set of CDMOs (Lonza, Catalent, Samsung, WuXi) and specialized vendors, giving suppliers strong leverage with 12–24 week lead times and MCB timelines of 6–12 months. Niche CRO/hepatology capacity and biomarker labs (26,000 CLIA labs in US, few qualified for NASH) plus a $62.5B CRO market (2024) drive premium pricing and switching risk. Long-term contracts and capacity reservations are essential to mitigate delays.
| Metric | 2024 Value |
|---|---|
| Global CRO market | $62.5B |
| US CLIA labs | 26,000 |
| CDMO lead times | 12–24 weeks |
| MCB dev. | 6–12 months |
What is included in the product
Detailed Word Document
Concise Porter’s Five Forces overview for 89bio highlighting competitive rivalry, buyer and supplier influence on pricing, barriers deterring new entrants, threats from substitutes and disruptive biotech innovations, and implications for 89bio’s market positioning and profitability.
Customizable Excel Spreadsheet
A clear one-sheet Porter's Five Forces for 89bio—distills competitive threats, supplier/buyer power, substitutes, and entry barriers into a concise view for rapid, boardroom-ready decision-making.
Customers Bargaining Power
Payers and HTA bodies
Payers and HTA bodies will demand robust histologic and hard clinical outcomes for NASH and CV risk reduction in SHTG, driven by NAFLD/NASH affecting ~25% of the global population. High budget impact from this large patient pool intensifies price scrutiny and access controls, making outcomes-based contracts likely. Clear superiority versus GLP-1s or THR-beta agents would materially reduce buyer leverage.
Specialists and treatment centers
Hepatologists, endocrinologists and lipidologists act as prescribing gatekeepers for 89bio, comparing efficacy, tolerability, dosing convenience and combo potential; specialists account for >50% of advanced NASH specialty prescriptions. Strong guideline inclusion and KOL advocacy historically increase uptake and can cut buyer bargaining power by shifting demand to manufacturers. Conversely, complex monitoring requirements—labs, imaging, specialist follow‑up—raise centers' leverage and slow adoption.
Patient affordability and adherence
Injectable biologics face pronounced co-pay sensitivity, with studies through 2024 reporting up to 30% of patients delaying or abandoning high-cost biologics for affordability reasons, creating adherence friction. Patient assistance programs and simpler dosing regimens can boost uptake but transfer cost pressure to manufacturers and payers, often cutting patient out-of-pocket by >50%. If oral or lifestyle options (fibrates, omega-3s) are acceptable and cheaper, buyers gain leverage. Clear symptomatic and TG reductions in SHTG can blunt price sensitivity.
Procurement consolidation
PBMs and specialty pharmacies aggregate demand and negotiate large rebates for 89bio therapies; the top 3 US PBMs control roughly 80% of prescription volume, specialty drugs now drive about 50% of US drug spend, and rebates for biologics/specialty classes often reach 30–40%. Formulary tiering and prior authorization increase buyer leverage, real-world evidence is shaping renewal and value-based terms (now ~10% of commercial deals), and narrow networks further compress net pricing.
- PBM concentration ~80%
- Specialty = ~50% of spend
- Rebates often 30–40%
- Value-based contracts ~10%
- Narrow networks compress net pricing
Indication mix and unmet need
- NASH prevalence: up to 25% adults, progressive NASH ~3–5%
- SHTG: biomarker-driven response supports targeted value
- Clinical differentiation reduces customer bargaining power
- Ambiguous endpoints increase payer selectivity
NAFLD drugs face payer pressure: outcomes-based deals, PBM rebates, and monitoring burdens
Payers/HTAs demand hard outcomes; NAFLD affects ~25% of adults, driving price scrutiny and outcomes-based deals. Specialists and guideline placement can lower buyer power, but monitoring burden and copay sensitivity give payers and patients leverage. PBM concentration (~80%) and rebates (30–40%) amplify negotiating clout, while clear clinical differentiation reduces it.
| Metric | Value |
|---|---|
| NAFLD prevalence | ~25% |
| Progressive NASH | 3–5% |
| PBM concentration (top 3) | ~80% |
| Specialty drug spend | ~50% |
| Typical rebates | 30–40% |
| Value-based deals | ~10% |
Same Document Delivered
89bio Porter's Five Forces Analysis
This preview shows the exact 89bio Porter's Five Forces Analysis you'll receive immediately after purchase—no surprises, no placeholders. The document displayed is the same professionally written, fully formatted analysis ready for download and use the moment you buy. You're looking at the actual deliverable with instant access upon payment.
Rivalry Among Competitors
Approved and late-stage NASH competitors
Madrigal’s resmetirom, with reported ~50% relative liver‑fat reduction and ~20% LDL drop in pivotal data, sets a regulatory and commercial benchmark in MASH/NASH with fibrosis, raising the bar for approval and pricing; THR‑beta class competition intensifies positioning pressure for FGF21 analogs (showing fibrosis signal across trials), creating near head‑to‑head expectations and forcing differentiation on fibrosis endpoints, lipids and non‑invasive markers.
FGF21 class peers
Akero’s efruxifermin is a direct class competitor to 89bio with overlapping NASH/MAFLD indications, making head-to-head comparisons on liver fat, fibrosis regression, and metabolic endpoints central to rivalry. Safety profile, dosing frequency, and durability of response will likely decide market share. Subtle trial design differences—endpoints, biopsy timing, and patient selection—can markedly shift perceived advantage.
Metabolic powerhouses with incretin platforms
Novo Nordisk and Eli Lilly push GLP-1/GIP agents with clear liver‑fat and weight benefits—STEP-1 semaglutide showed ~14.9% mean weight loss and SURMOUNT-1 tirzepatide ~22.5%—intensifying competition. Lifecycle and combo strategies target overlapping patient pools, raising share stakes. Primary care distribution of these agents challenges specialty biologics. Superior NASH histology or combo synergy could blunt that advantage.
SHTG lipid-lowering innovators
Race for payer and guideline mindshare
First-to-market status and guideline inclusion create durable advantages for 89bio, anchoring payer preference and a higher baseline price realization; top three PBMs cover about 70% of US prescription claims (2024), amplifying the payoff for early coverage. Real-world data and HEOR will decide formulary placement and utilization management. Companion diagnostics or NITs can franchise use by making switching costly. Sales force scale and strategic partnerships magnify these effects.
- First-to-market: guideline lock-in
- RWE/HEOR: formulary battlegrounds, PBMs ~70% (2024)
- Companion diagnostics/NITs + sales scale = durable uptake
Strong liver-fat and LDL efficacy raises bar as GLP-1/GIP overlap and PBM control shape market
Madrigal’s resmetirom (~50% liver‑fat ↓, ~20% LDL ↓) sets a high regulatory/commercial bar, intensifying direct THR‑beta and FGF21 rivalry; Akero’s efruxifermin and GLP1/GIP (semaglutide ~14.9% weight ↓, tirzepatide ~22.5%) create overlapping indications. Lipid programs (APOC3 ~70% TG ↓, ANGPTL3 30–50%) raise differentiation needs; PBM/formulary control (~70% US claims) will decide share.
| Asset | Key metric |
|---|---|
| Resmetirom | ~50% liver‑fat ↓; ~20% LDL ↓ |
| Semaglutide | ~14.9% weight ↓ |
| Tirzepatide | ~22.5% weight ↓ |
| APOC3 | ~70% TG ↓ |
| ANGPTL3 | 30–50% TG ↓ |
SSubstitutes Threaten
Lifestyle modification
Diet, exercise and weight loss are first-line low-cost therapy; guidelines target 7–10% weight loss which in trials reduced liver fat and improved histology, and can lower triglycerides by ~20–30%. Real-world sustained weight-loss ≥5% at 1 year occurs in ~20–30% of patients, highlighting adherence challenges. Payers often require 6–12 month documented lifestyle trials before covering drugs, making this a persistent substitute for milder disease.
GLP-1/GIP and other metabolic drugs
GLP-1/GIP agents (tirzepatide/semaglutide) deliver up to ~20%+ weight loss and 30–60% hepatic fat reductions in trials, sometimes achieving sufficient metabolic control to obviate NASH-specific therapy. Oral THR-beta (resmetirom) offers a pill alternative with meaningful steatosis reductions in late‑stage trials. SGLT2s, pioglitazone and vitamin E remain niche options for subsets. Convenience and lower cost can displace injectables absent clear superior outcomes.
Bariatric and endoscopic procedures
Surgical and endoscopic weight-loss interventions deliver durable metabolic benefits, with bariatric procedures producing average total weight loss of 20–35% and diabetes remission rates up to 60–80% at 1–5 years. For eligible patients studies show NASH resolution in ~50–60% and meaningful dyslipidemia improvements. High upfront costs ($15k–$35k) but superior efficacy pose a strong substitute to drugs. Limited access, eligibility criteria and perioperative risks constrain broad substitution.
Omega-3 and lipid therapies
High-dose EPA (4 g/day) and EPA-combination products are entrenched for hypertriglyceridemia; REDUCE-IT reported ~25% relative risk reduction in major adverse CV events and high-dose EPA yields ~20–30% TG lowering in SHTG cohorts. These agents are familiar and widely accessible, while multiple generic omega-3s exert strong price pressure versus branded therapies. 89bio needs clear superiority on TG lowering and hard outcomes to avoid substitution.
- 25% RRR in REDUCE-IT vs placebo
- 20–30% TG lowering with high-dose EPA
- Generics often >50% cheaper, driving price pressure
Supportive care and watchful waiting
Supportive care and watchful waiting act as a meaningful substitute for 89bio by enabling clinicians to defer pharmacologic intervention when patients are asymptomatic or lack coverage; global NAFLD prevalence is about 25% of adults and roughly 20% of those have NASH, creating a large pool managed conservatively in 2024. Monitoring with noninvasive tests (NITs) and lifestyle advice can cover short-term needs, undermining uptake in borderline fibrosis cases, though robust phase 2/3 data showing fibrosis progression reduction would reduce this threat.
- NAFLD prevalence ~25% (2024)
- NASH among NAFLD ~20%
- Watchful waiting common for asymptomatic/borderline fibrosis
- Strong antifibrotic evidence can reverse substitution risk
GLP-1/GIP ~20%+ WL vs bariatric 20–35%
Low-cost lifestyle therapy achieves sustained ≥5% weight loss in ~20–30% at 1 year, often required by payers. GLP-1/GIP drugs deliver ~20%+ weight loss; oral resmetirom and generics offer cheaper pill options. Bariatric surgery yields 20–35% total weight loss at $15k–$35k. NAFLD prevalence ~25% in 2024; ~20% of NAFLD have NASH.
| Substitute | Key metric | Impact |
|---|---|---|
| Lifestyle | 20–30% ≥5% WL at 1 yr | High payor barrier |
| GLP-1/GIP | ~20%+ WL | Strong clinical substitute |
| Bariatric | 20–35% WL; $15k–$35k | Durable, limited access |
Entrants Threaten
High clinical and regulatory hurdles
NASH phase 3 programs typically enroll 1,500–3,000 patients, run 48–72 weeks with liver biopsy or validated NITs, and can cost $200–500M, creating major capital barriers. High failure rates in late-stage NASH and the lack of an FDA-approved antifibrotic therapy as of 2024 deter new entrants. Evolving FDA/EMA guidance on surrogate endpoints and antifibrotic evidence increases regulatory complexity and risk.
Manufacturing and CMC complexity
Engineering stable, scalable PEGylated FGF21 biologics is technically demanding, with formulation and conjugation challenges that extend development timelines. GMP capacity, advanced analytics, and comparability testing create high fixed barriers and supplier lead times that in 2024 commonly exceed 9–12 months. New entrants face long qualification windows for suppliers and CROs, and CMC setbacks frequently add 12–24 months or can derail programs entirely.
IP, data, and class know-how
By 2024 89bio faces patent thickets around FGF21 designs, formulations, and dosing—dozens of issued and pending claims that raise freedom-to-operate analyses, adding months and typically $0.5–2M in legal and clearance costs. Clinical know-how and KOL relationships built across FGF21 trials are cumulative advantages that newcomers can rarely match quickly. Elevated litigation risk, with patent suits often costing millions, further deters entry.
Commercial access and payer evidence
Building payer dossiers, HEOR programs and outcomes evidence requires multi-year, multi-million-dollar investment, limiting entrants that lack head-to-head trials or robust RWE and thereby restricting commercial access for new competitors in 2024. Established players set pricing anchors that shape formularies and reimbursement thresholds, while sophisticated contracting and value-based arrangements act as a commercial moat.
- Barriers: high HEOR/RWE cost
- Evidence: lack of head-to-head limits access
- Pricing: incumbents set anchors
- Moat: advanced contracting sophistication
Capital markets and partner dependence
Clinical-stage biotechs depend on volatile capital markets and selective big‑pharma partnerships; with venture and public financing down (biotech VC investment fell about 28% from the 2021 peak to 2024) and alliance deals increasingly milestone‑driven, funding gates and partner selectivity materially reduce the threat of new entrants.
- High capital intensity
- ~28% drop in VC funding (2021–2024)
- Milestone‑based big‑pharma deals
- Short cash runways limit new entrants
High NASH Phase 3 costs and long timelines plus patent and supply hurdles deter entrants
High capital and long development timelines (NASH phase 3: $200–500M, 48–72 weeks) create strong entry barriers. Complex CMC, PEG‑FGF21 formulation challenges and supplier lead times (9–12 months) raise technical risk. Patent thickets and legal clearance (~$0.5–2M) plus −28% biotech VC funding (2021–2024) and milestone deals reduce entrant threat.
| Metric | 2024 value |
|---|---|
| NASH Phase 3 cost | $200–500M |
| Trial duration | 48–72 weeks |
| Supplier lead times | 9–12 months |
| Patent/legal cost | $0.5–2M |
| VC funding change | −28% (2021–2024) |